Zacks Investment Research cut shares of Zealand Pharma A/S (NASDAQ:ZLDPF) from a hold rating to a sell rating in a research report report published on Tuesday morning.

According to Zacks, “Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company’s pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark. “

Zealand Pharma A/S (NASDAQ:ZLDPF) traded up 1.36% during midday trading on Tuesday, hitting $18.70. The stock had a trading volume of 1,000 shares. The stock has a 50 day moving average of $18.69 and a 200 day moving average of $17.65. Zealand Pharma A/S has a 12 month low of $14.95 and a 12 month high of $19.51. The stock’s market cap is $478.91 million.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at

Get a free copy of the Zacks research report on Zealand Pharma A/S (ZLDPF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with's FREE daily email newsletter.